Boehringer Ingelheim’s podcast called Taking Cancer On is back with episode 3. Hosted by Sebastian Hermelin, co-founder of War On Cancer, this new episode talks about the power of research partnerships in progressing cancer innovation and drug development.
Episode 3: Collaborating Against Cancer
Expert Guests: In this episode, we hear from Dr Scott DeWire, Head of US Business Development at Boehringer Ingelheim (BI) and Dr. Andrew Fadden, Head of Corporate Development at Enara Bio. Their
discussion proves that embracing collaboration is essential in delivering ground-breaking treatments to people going through cancer, faster.
This episode dives into Scott and Andrew’s work and views of the importance of the patient voice in pharmaceutical partnerships, Boehringer Ingelheim and Enara Bio’s partnership to progress cancer innovation and drug development forward, and pharmaceutical collaborations as a whole – what is needed to improve cancer care.
Take a listen to episode 3 here.
About Taking Cancer On – The Podcast
In an effort to simplify the science behind Boehringer Ingelheim’s ambition to ‘drug the undruggable’, this podcast draws back the curtain on cancer research and takes a look at its complex inner workings. Hosted by Sebastian Hermelin (co-founder of the War On Cancer app), each episode welcomes a new expert guest who takes the listener through one of the many stages of cancer research and drug development; from early discovery efforts, through to clinical trials and drug approval.
If you haven’t already, make sure to listen to episode 2 about clinical trials for cancer, with Dr Victoria Zazulina, Corporate Vice President and Global Head of Oncology Medicine at Boehringer Ingelheim and Ivy Elkins, lung cancer survivor and advocate and co-founder of the EGFR.
Or, listen to the War On Cancer podcast episode about how Health Studies in the War On Cancer app is progressing cancer research and care forward by making it patient-centric.
